Maintenance olaparib rechallenge in patients (pts) with ovarian carcinoma (OC) previously treated with a PARP inhibitor (PARPi): Phase IIIb OReO/ENGOT Ov-38 trial

Simple item page
dc.conference.dateSEP 16-21, 2021
dc.conference.titleCongress of the European-Society-for-Medical-Oncology (ESMO)
dc.contributor.authorPujade-Lauraine, E.
dc.contributor.authorSelle, F.
dc.contributor.authorScambia, G.
dc.contributor.authorAsselain, B.
dc.contributor.authorMarme, F.
dc.contributor.authorLindemann, K.
dc.contributor.authorColombo, N.
dc.contributor.authorMadry, R.
dc.contributor.authorGlasspool, R. M.
dc.contributor.authorDubot, C.
dc.contributor.authorOaknin, A.
dc.contributor.authorZamagni, C.
dc.contributor.authorHeitz, F.
dc.contributor.authorGladieff, L.
dc.contributor.authorRubio-Perez, M. J.
dc.contributor.authorScollo, P.
dc.contributor.authorBlakeley, C.
dc.contributor.authorShaw, B.
dc.contributor.authorRay-Coquard, I. L.
dc.contributor.authorRedondo, A.
dc.contributor.authoraffiliation[Pujade-Lauraine, E.] ARCAGY GINECO, Med Oncol, Paris, France
dc.contributor.authoraffiliation[Selle, F.] Grp Hosp Diaconesses Croix SaintSimon &, Dept Med Oncol, Paris, France
dc.contributor.authoraffiliation[Scambia, G.] IRCCS, Fnd Policlin Univ Gemelli, UOC Ginecol Oncol & MITO, Dipa Salute Donna Bambino Salute Pubbl, Rome, Italy
dc.contributor.authoraffiliation[Asselain, B.] ARCAGY GINECO, Stat, Paris, France
dc.contributor.authoraffiliation[Marme, F.] Univ Hosp Mannheim & AGO, Gynecol Oncol Dept, Mannheim, Germany
dc.contributor.authoraffiliation[Lindemann, K.] Univ Oslo & NSGO, Oslo Univ Hosp, Fac Med, Inst Clin Med,Dept Gynaecolog Oncol, Oslo, Norway
dc.contributor.authoraffiliation[Colombo, N.] Univ Milan Bicocca & MANGO, European Inst Oncol IRCCS, Gynecol Canc Program, Milan, Italy
dc.contributor.authoraffiliation[Madry, R.] Szpital Kliniczny Przemienienia Panskiego Uniwer, Katedra Klinika Onkologii, Poznan, Poland
dc.contributor.authoraffiliation[Glasspool, R. M.] Univ Glasgow & NCRI, Beatson West Scotland Canc Ctr, Inst Canc Sci, Med Oncol Dept, Glasgow, Lanark, Scotland
dc.contributor.authoraffiliation[Dubot, C.] Inst Curie St Cloud & GINECO, Oncol Medicale, Paris, France
dc.contributor.authoraffiliation[Oaknin, A.] Hosp Univ Vall dHebron, Vall dHebron Barcelona Hosp Campus & GEICO, Vall dHebron Inst Oncol VHIO, Gynaecol Canc Programme, Barcelona, Spain
dc.contributor.authoraffiliation[Zamagni, C.] IRCCS Azienda Osped univ Bologna, Oncol Med, Bologna, Italy
dc.contributor.authoraffiliation[Heitz, F.] Univ Berlin, Berlin Inst Hlth & AGO, Ctr Oncol Surg Charite Campus, Dept Gynecol & Gyne colog Oncol, Essen, Germany
dc.contributor.authoraffiliation[Gladieff, L.] Inst Claudius Regaud IUCTOncopole & GINECO, Med Oncol, Toulouse, France
dc.contributor.authoraffiliation[Rubio-Perez, M. J.] Reina Sofia Univ Hosp & GEICO, Med Oncol, Cordoba, Spain
dc.contributor.authoraffiliation[Scollo, P.] Osped Cannizzaro & MITO, Dipt Ginecologia Ostetricia, Catania, Italy
dc.contributor.authoraffiliation[Blakeley, C.] AstraZeneca, Cambridge, England
dc.contributor.authoraffiliation[Shaw, B.] AstraZeneca, Cambridge, England
dc.contributor.authoraffiliation[Ray-Coquard, I. L.] Univ Claude Bernard Lyon, Ctr Leon Berard, Med Oncol, Lyon, France
dc.contributor.authoraffiliation[Redondo, A.] Paz Univ Hosp & GEICO, Med Oncol, Madrid, Spain
dc.contributor.funderAstraZeneca
dc.date.accessioned2025-01-07T13:13:00Z
dc.date.available2025-01-07T13:13:00Z
dc.date.issued2021-09-21
dc.identifier.doi10.1016/j.annonc.2021.08.2110
dc.identifier.essn1569-8041
dc.identifier.issn0923-7534
dc.identifier.unpaywallURLhttps://doi.org/10.1016/j.annonc.2021.08.2110
dc.identifier.urihttps://hdl.handle.net/10668/25339
dc.identifier.wosID700527703509
dc.issue.number5
dc.journal.titleAnnals of oncology
dc.journal.titleabbreviationAnn. oncol.
dc.language.isoen
dc.organizationSAS - Hospital Universitario Reina Sofía
dc.page.numberS1308-S1309
dc.publisherElsevier
dc.rights.accessRightsopen access
dc.titleMaintenance olaparib rechallenge in patients (pts) with ovarian carcinoma (OC) previously treated with a PARP inhibitor (PARPi): Phase IIIb OReO/ENGOT Ov-38 trial
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number32
dc.wostypeMeeting Abstract

Files

Collections

SAS - Hospital Universitario Reina Sofía

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía